Latest news with #DexCom
Yahoo
6 days ago
- Business
- Yahoo
DexCom (DXCM) Extends Losses on Day 5 Amid Leadership Change
We recently published . DexCom, Inc. (NASDAQ:DXCM) is one of the companies that stood stronger last week. DexCom fell for a fifth straight day on Monday, shedding 3.82 percent to close at $76.25 apiece as investors turned cautious following the announcement of a leadership change after the company's strong earnings performance in the second quarter of the year. In a statement last week, DexCom, Inc. (NASDAQ:DXCM) named Jake Leach as its new chief executive officer (CEO) effective January 1, 2026, in addition to his post as the current president and chief operating officer. Incumbent CEO Kevin Sayer will continue to work closely with Leach during the transition period and remain executive chairman of the board of directors. Meanwhile, DexCom, Inc. (NASDAQ:DXCM) grew its net income in the second quarter of the year by 25 percent to $179.8 million from $143.5 million in the same period last year. Revenues increased by 16 percent to $1.16 billion from $1 billion year-on-year. While we acknowledge the potential of DXCM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-08-2025
- Business
- Yahoo
Masimo (MASI) Reports Q2: Everything You Need To Know Ahead Of Earnings
Medical tech company Masimo (NASDAQ:MASI) will be reporting earnings this Tuesday afternoon. Here's what investors should know. Masimo beat analysts' revenue expectations by 1.1% last quarter, reporting revenues of $372 million, up 9.5% year on year. It was a mixed quarter for the company, with an impressive beat of analysts' constant currency revenue estimates but a significant miss of analysts' full-year EPS guidance estimates. Is Masimo a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Masimo's revenue to grow 7.2% year on year to $368.7 million, a reversal from the 24.5% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.22 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Masimo has missed Wall Street's revenue estimates six times over the last two years. Looking at Masimo's peers in the patient monitoring segment, some have already reported their Q2 results, giving us a hint as to what we can expect. iRhythm delivered year-on-year revenue growth of 26.1%, beating analysts' expectations by 7.3%, and DexCom reported revenues up 15.2%, topping estimates by 2.8%. iRhythm traded up 17.6% following the results while DexCom was down 9.3%. Read our full analysis of iRhythm's results here and DexCom's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the patient monitoring stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Masimo is down 3.3% during the same time and is heading into earnings with an average analyst price target of $184.43 (compared to the current share price of $157.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
30-07-2025
- Business
- Yahoo
DexCom (DXCM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
The upcoming report from DexCom (DXCM) is expected to reveal quarterly earnings of $0.45 per share, indicating an increase of 4.7% compared to the year-ago period. Analysts forecast revenues of $1.12 billion, representing an increase of 11.8% year over year. Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock. While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective. In light of this perspective, let's dive into the average estimates of certain DexCom metrics that are commonly tracked and forecasted by Wall Street analysts. Analysts forecast 'Revenue- Hardware' to reach $38.99 million. The estimate indicates a year-over-year change of -32%. It is projected by analysts that the 'Revenue- Sensor and other' will reach $1.08 billion. The estimate suggests a change of +14.5% year over year. According to the collective judgment of analysts, 'Revenue- United States' should come in at $809.70 million. The estimate indicates a change of +10.6% from the prior-year quarter. The combined assessment of analysts suggests that 'Revenue- International' will likely reach $311.29 million. The estimate indicates a year-over-year change of +14.3%. View all Key Company Metrics for DexCom here>>> Over the past month, DexCom shares have recorded returns of +3.1% versus the Zacks S&P 500 composite's +4.9% change. Based on its Zacks Rank #2 (Buy), DXCM will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
21-07-2025
- Business
- Yahoo
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years
Key Points DexCom has barely scratched the surface of its niche in the diabetes market. As a result of industry challenges, the stock's valuation has now come down. But from here, the stock looks well-positioned to deliver excellent results. 10 stocks we like better than DexCom › Medical device specialist DexCom (NASDAQ: DXCM) has encountered significant headwinds in the past year. The company's financial results haven't been quite up to the market's standards, and broader market volatility caused by President Donald Trump's trade policies isn't helping either. The stock is down 26% over the trailing-12-month period. Yet even with all these challenges, DexCom could be a terrific performer in the next five years. Here's why. There's plenty of white space ahead DexCom markets continuous glucose monitoring (CGM) systems, which are devices that help track blood sugar levels in patients with diabetes. CGMs have at least two advantages: They make measurements automatically, and they make them as often as every five minutes. Consistently monitoring blood glucose levels helps people with diabetes make better health decisions. That's why CGM devices lead to improved outcomes, including less time spent in hyperglycemia. DexCom has significantly increased its installed base over the years. In 2024, it had over 2.5 million customers worldwide. However, the company remains well-positioned to capitalize on a massive global opportunity. In the U.S., DexCom estimates that there are more than 4.5 million diabetes patients on insulin therapy who aren't on CGM yet despite being eligible for third-party coverage for the technology. And that's just the U.S., one of the more advanced countries in terms of CGM penetration. DexCom has typically targeted patients who use insulin, and third-party payers have been more willing to cover these populations. However, last year, it launched Stelo, an over-the-counter CGM option for diabetes patients who aren't on insulin and for people with prediabetes. This move significantly expanded the company's addressable market. CGM penetration in the U.S. for type 2 diabetes patients not on insulin is about 5%, and for prediabetes patients less than 1%. DexCom's opportunities both within and outside the U.S. are massive. The increased adoption of CGM technology has helped its revenue and earnings grow steadily over the past decade, and this trend is likely to continue. DexCom's shares declined last year due to poor financial results; in the U.S., more patients than the company expected took advantage of rebates, leading to lower-than-expected revenue per customer. However, since there's still plenty of work to be done in the CGM market, DexCom can address that issue as it continues to make even more headway in this field. That will allow its financial results to improve. Are DexCom's shares too expensive? The stock's forward price-to-earnings ratio was recently 41.5, much higher than the healthcare sector's average of 15.8. But that forward P/E is on the low end compared to DexCom's average over the past few years: The medical device specialist has historically had steep valuation metrics, but has delivered market-beating returns anyway. In my view, DexCom can do the same in the next five to 10 years. Investors might also be concerned about DexCom's main competitor in the CGM market, Abbott Laboratories. But these rivals have battled it out for years, and there's more than enough space for both to be successful, given the large worldwide CGM opportunity. Furthermore, DexCom benefits from a network effect, as multiple companies have developed devices for diabetes patients that are compatible with its technology; these include insulin pens and pumps, third-party apps, and the Apple Watch. The more DexCom's installed base increases, the more attractive its ecosystem becomes to device or app developers looking to target a large population of patients. And as these companies launch more technologies compatible with DexCom's CGM devices, they also become more appealing to patients. This dynamic makes it likely that DexCom will remain a leader in CGM well beyond the next five years. In the meantime, the stock could rebound from its poor performance last year, and deliver superior returns through the end of the decade. Do the experts think DexCom is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did DexCom make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,048% vs. just 180% for the S&P — that is beating the market by 867.59%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories and Apple. The Motley Fool recommends DexCom and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy. Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years was originally published by The Motley Fool
Yahoo
07-07-2025
- Business
- Yahoo
What You Need to Know Ahead of DexCom's Earnings Release
DexCom, Inc. (DXCM), a San Diego-based medical device company with a $32.5 billion market cap, specializes in continuous glucose monitoring (CGM) systems. Its technology includes a small, implantable sensor that tracks glucose levels beneath the skin and transmits data to an external receiver in real-time. DexCom is slated to report its fiscal 2025 second-quarter earnings after the market closes on Wednesday, July 30. Ahead of the event, analysts expect DXCM to report a profit of $0.45 per share on a diluted basis, up 4.7% from $0.43 per share in the year-ago quarter. The company beat the consensus estimates in two of the last four quarters while missing the forecast on two other occasions. Chevron Stock's 4.6% Dividend Yield and 1.67% One Month Short Put Yield Make CVX a Buy Tariff Dealine, Fed Minutes and Other Key Thing to Watch this Week SoFi Stock Is Betting on Crypto Again. How Should You Play SOFI Stock Here? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For the full year, analysts expect DXCM to report EPS of $2.03, up 23.8% from $1.64 in fiscal 2024. Its EPS is expected to rise 24.6% year over year to $2.53 in fiscal 2026. Over the past 52 weeks, DXCM's shares have dipped 25.2%, underperforming the S&P 500's ($SPX) 13.4% gains and the Health Care Select Sector SPDR Fund's (XLV) 5.4% dip over the same time frame. On July 1, DexCom shares fell over 4% after the U.S. government proposed changes to payment schedules and introduced a competitive bidding program for diabetes devices, impacting the broader glucose monitoring and insulin pump sector. Nevertheless, analysts' consensus opinion on DXCM stock is very positive, with an overall 'Strong Buy' rating. Out of 25 analysts covering the stock, 20 advise a 'Strong Buy' rating, one suggests a 'Moderate Buy,' and four give a 'Hold.' DXCM's average analyst price target is $99.68, indicating a potential upside of 20.2% from the current levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
